About Prescrire

Major medical journals rely on our publications

La Revue Prescrire and Prescrire International have led a pioneering effort, providing unmatched reviews and systematic analyses of evaluation data on practically all newly approved drugs and indications. This endeavor is guided by evidence-based principles and a patient-centered perspective. Our work has earned acclaim and served as a cornerstone for research published in top-tier international journals, for example:

Lexchin J "Therapeutic benefit from new drugs from pharmaceutical companies " JAMA Intern Med 2024; 184 (1): 52-53.

Brinkhuis F et al. "Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study " BMJ 2024; 384: e077391.

Osipenko L et al. "Provenance and clinical benefit of medicines introduced to the French market, 2008 to 2018 " JAMA Intern Med 2024; 184 (1): 46-52.

Osipenko L et al. "The origin of first-in-class drugs: innovation versus clinical benefit " Clin Pharmacol Ther 2024; 115 (2): 342-348.

Patel NG et al. "Therapeutic value of drugs frequently marketed using direct-to-consumer television advertising, 2015 to 2021 " JAMA Netw Open 2023; 6 (1): e2250991.

Vitry A and Mintzes B ""Drugs to avoid" to improve quality use of medicines: how is Australia faring? " J Pharm Policy Pract 2021; 14 (1): 60.

Hwang TJ et al. "Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study " BMJ 2020; 371: m3434.

Walsh S et al. "France removes state funding for dementia drugs" BMJ 2019; 367: l6930.